Rex function and the interaction of cellular proteins with the cis-acting repressive sequences (CRS) within HTLV-II RNA (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Rex function and the interaction of cellular proteins with the cis-acting repressive sequences (CRS) within HTLV-II RNA (Meeting abstract).

International Association for Comparative Research on Leukemia and Related Diseases, 16th Symposium. July 11-16, 1993, Montreal, Quebec, Canada, A39, 1993.. Unique Identifier : AIDSLINE ICDB/94698641
Black AC; Ruland CT; Bakker A; Luo J; Rosenblatt JD; Div. of Hematology/Oncology, Dept. of Medicine, UCLA Sch. of; Medicine, Los Angeles, CA 90024-1678


Abstract: The shift from viral regulatory to structural gene expression in human T-cell leukemia viruses (HTLVs) and human immunodeficiency viruses (HIVs) is mediated by Rex and Rev, respectively. Both Rev and Rex interact with cognate RNA response elements to overcome the inhibitory effects of cis-acting repressive elements located elsewhere in the genome. We previously showed that HTLV-II responsive element (RxRE) in 5' long terminal repeat (LTR) RNA. HTLV-II Rex acts through the RxRE to increase cytoplasmic levels of gag/pol mRNA by overcoming the block to nuclear export conferred by cis-acting repressive sequences (CRS) between nucleotides (nt) +208 to +317 in the 5' LTR. We demonstrate by electrophoretic mobility-shift assay that cellular proteins in a HeLa nuclear extract bind specifically to transcripts containing the HTLV-II CRS. Using UV cross-linking of gel-retarded bands, we identified a major protein species of approximately 60 kD that specifically binds to the CRS. Cross competition binding assays and UV cross-linking suggest that this 60 kD protein may interact with another 40 kD protein that binds to downstream RNA from nt +332 to +436. HTLV-II CRS function in a transient transfection assay correlates with 40 kD protein interaction with HTLV-II CRS RNA. Both the 60 kD and 40 kD cellular proteins also bind to HIV-1 RNAs that contain previously described CRS elements, suggesting similar underlying mechanisms of action. These data suggest that Rex and Rev may interact with the CRS binding proteins to facilitate expression of viral mRNA containing the CRS. The nature of these cellular proteins is under investigation in our laboratory.
Keywords: Amino Acid Sequence Gene Products, gag/GENETICS Gene Products, pol/GENETICS Gene Products, rev/*GENETICS Gene Products, rex/*GENETICS Hela Cells Human HIV Long Terminal Repeat/GENETICS HIV-1/GENETICS HTLV-II/*GENETICS RNA, Messenger/METABOLISM RNA, Viral/GENETICS/METABOLISM Transfection ABSTRACTKWDaminoacidsequencegeneproducts,gag/geneticsgeneproducts,pol/geneticsgeneproducts,rev/KWDgeneticsgeneproducts,rex/KWDgeneticshelacellshumanhivlongterminalrepeat/geneticshiv-1/geneticshtlv-ii/KWDgeneticsrna,messenger/metabolismrna,viral/genetics/metabolismtransfectionabstract
940830
M9480800

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .